Yes on the face of it, it appears good news but as normal I have to question why the safety committee hasn't already given permission for cohort 1 patients to move to cohort 3 as final patient from cohort 1 was dosed in January and if even if they get permission to move cohort 1 patients to cohort 3 on 18 May then 28 days at higher dose and wait for data and the safety committee's approval before cohort 2 can move to cohort 2 to cohort 4 do they expect the trial to be completed by mid year
Ann: Progress update on Phase 1/2 MND interim analysis, page-20
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $92.46M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.0¢ | 19.0¢ | $118.1K | 605.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 271759 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 84950 | 5 |
View Market Depth
| Last trade - 15.35pm 08/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |